skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment

Abstract

Purpose: Ibandronate is a single-nitrogen, noncyclic bisphosphonate with proven efficacy for reducing metastatic bone pain. In this study, we assessed the palliative effects of combined ibandronate and radiotherapy. Methods and Materials: Forty-five patients with bone metastases from various solid tumors received external-beam radiotherapy, 30-40 Gy over 3-4.5, weeks combined with 10 cycles of monthly intravenous ibandronate, 6 mg. Results: After combined therapy, mean bone pain scores (graded from 0 to 10) were reduced from 6.3 at baseline to 0.8 after 3 months, with further reductions at later time points (all p < 0.001). Opioid use decreased from 84% of patients at baseline (38/45) to 24% (11/45) at 3 months, with further subsequent reductions (all p < 0.001). Mean performance status and functioning scores also significantly improved. Bone density (assessed by computed tomography scan) increased by 20% vs. baseline at 3 months, 46% at 6 months, and 73% at 10 months (all p < 0.001). Lesion improvement was also demonstrated by magnetic resonance imaging. Treatment was well tolerated with no renal toxicity. Conclusions: In this pilot study, combined radiotherapy and ibandronate provided substantial bone pain relief and increased bone density. Computed tomography-based or magnetic resonance imaging-based evaluations offer objective methods formore » assessing therapeutic outcomes.« less

Authors:
 [1];  [2];  [1];  [2];  [3];  [4]
  1. Department of Radiotherapy, University of Patras Medical School, Patras (Greece)
  2. Department of Radiology, University of Patras Medical School, Patras (Greece)
  3. Laboratory of Public Health, University of Patras Medical School, Patras (Greece)
  4. Department of Radiotherapy, University of Patras Medical School, Patras (Greece). E-mail: kardim@med.upatras.gr
Publication Date:
OSTI Identifier:
20850324
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 67; Journal Issue: 1; Other Information: DOI: 10.1016/j.ijrobp.2006.08.022; PII: S0360-3016(06)02755-6; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; COMBINED THERAPY; COMPUTERIZED TOMOGRAPHY; EVALUATION; METASTASES; NEOPLASMS; NMR IMAGING; PAIN; PATIENTS; PERFORMANCE; RADIOTHERAPY; SKELETON; TOXICITY

Citation Formats

Vassiliou, Vassilios, Kalogeropoulou, Christine, Christopoulos, Christos, Solomou, Ekaterini, Leotsinides, Michael, and Kardamakis, Dimitrios. Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment. United States: N. p., 2007. Web. doi:10.1016/j.ijrobp.2006.08.022.
Vassiliou, Vassilios, Kalogeropoulou, Christine, Christopoulos, Christos, Solomou, Ekaterini, Leotsinides, Michael, & Kardamakis, Dimitrios. Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment. United States. doi:10.1016/j.ijrobp.2006.08.022.
Vassiliou, Vassilios, Kalogeropoulou, Christine, Christopoulos, Christos, Solomou, Ekaterini, Leotsinides, Michael, and Kardamakis, Dimitrios. Mon . "Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment". United States. doi:10.1016/j.ijrobp.2006.08.022.
@article{osti_20850324,
title = {Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment},
author = {Vassiliou, Vassilios and Kalogeropoulou, Christine and Christopoulos, Christos and Solomou, Ekaterini and Leotsinides, Michael and Kardamakis, Dimitrios},
abstractNote = {Purpose: Ibandronate is a single-nitrogen, noncyclic bisphosphonate with proven efficacy for reducing metastatic bone pain. In this study, we assessed the palliative effects of combined ibandronate and radiotherapy. Methods and Materials: Forty-five patients with bone metastases from various solid tumors received external-beam radiotherapy, 30-40 Gy over 3-4.5, weeks combined with 10 cycles of monthly intravenous ibandronate, 6 mg. Results: After combined therapy, mean bone pain scores (graded from 0 to 10) were reduced from 6.3 at baseline to 0.8 after 3 months, with further reductions at later time points (all p < 0.001). Opioid use decreased from 84% of patients at baseline (38/45) to 24% (11/45) at 3 months, with further subsequent reductions (all p < 0.001). Mean performance status and functioning scores also significantly improved. Bone density (assessed by computed tomography scan) increased by 20% vs. baseline at 3 months, 46% at 6 months, and 73% at 10 months (all p < 0.001). Lesion improvement was also demonstrated by magnetic resonance imaging. Treatment was well tolerated with no renal toxicity. Conclusions: In this pilot study, combined radiotherapy and ibandronate provided substantial bone pain relief and increased bone density. Computed tomography-based or magnetic resonance imaging-based evaluations offer objective methods for assessing therapeutic outcomes.},
doi = {10.1016/j.ijrobp.2006.08.022},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 1,
volume = 67,
place = {United States},
year = {Mon Jan 01 00:00:00 EST 2007},
month = {Mon Jan 01 00:00:00 EST 2007}
}